Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2017 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 5 April 2017 -...
February 28, 2017 01:01 ET | Source: Addex Therapeutics

Addex Raises CHF3.0 million Through Private Placement of Treasury Shares and Extends Cash Runway Through 2018

Geneva, Switzerland, 28 February 2017 - Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF3.0 million through a private placement in which 1.5 million treasury...
February 28, 2017 01:00 ET | Source: Addex Therapeutics

Addex Raises CHF3.0 million Through Private Placement of Treasury Shares and Extends Cash Runway Through 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 28 February 2017...
February 27, 2017 01:00 ET | Source: Addex Therapeutics

Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 27 February...
February 06, 2017 01:00 ET | Source: Addex Therapeutics

Addex's Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 6 February 2017 -...
January 31, 2017 01:00 ET | Source: Addex Therapeutics

Addex Awarded $835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson's Disease

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 31 January 2017 -...
January 09, 2017 01:00 ET | Source: Addex Therapeutics

Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain

Geneva, Switzerland, 9 January 2017 - Addex Therapeutics (SIX: ADXN), announced today that ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor...
January 09, 2017 01:00 ET | Source: Addex Therapeutics

Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 9 January 2017 -...
December 13, 2016 01:00 ET | Source: Addex Therapeutics

Addex ADX71441 Pharmacological Profile Published in Neuropharmacology

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 13 December 2016 -...
November 28, 2016 01:00 ET | Source: Addex Therapeutics

Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Dr Mills adds extensive expertise in...